First in Man Study of Pulsed Field Ablation System for the Treatment of Paroxysmal Atrial Fibrillation in 1 Patient

Inclusion criteria

• Patients aged 18 to 75 years old;
• Patients diagnosed with symptomatic paroxysmal atrial fibrillation: (The medical records documented recurrent and self-terminating atrial fibrillation).Electrocardiographic recordings may include, but are not limited to, electrocardiography (ECG), ambulatory ECG monitoring, or telemetric ECG.
• Capable and willing to comply with all preoperative and postoperative follow-up examinations and requirements.
• Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself.

Exclusion criteria

• AF secondary to electrolyte imbalance, thyroid disease, or reversible cause;
• AF episodes lasting more than 7 days;
• History of previous AF ablation therapy;
• Previous valve repair, replacement or artificial valve implantation; previous atrial septal defect closure, patent foramen ovale closure cardiac intervention or surgery;
• Any myocardial infarction (MI), coronary artery bypass grafting (CABG) procedure or percutaneous coronary intervention (PCI) during the 3-month interval preceding the consent date;
• Hypertrophic Obstructive Cardiomyopathy (HOCM);
• NYHA class III and IV;
• Presence of implanted ICD, CRT;
• Documented active thrombus in the left atrium or atrial appendage on imaging;
• Any carotid artery stent implantation or endarterectomy within the previous 6 months;
• Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gas or severe breathing difficulties;
• Known pulmonary vein stenosis
• Contraindication to isoproterenol therapy.
• Anticoagulation contraindications, and history of blood clotting or bleeding abnormalities;
• Patients with acute systemic infection;
• （eGFR）< 60mL/min/1.73m2, or have a history of kidney dialysis;
• Women who are pregnant and/or breast feeding or unable to use contraception during the trial;
• Enrollment in another clinical trial evaluating other devices or drugs during the same period;
• Life expectancy less than 12 months (such as patients with advanced cancer);
• Abnormalities or diseases that the investigator considers to be excluded from the study's coverage.